Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
2(13%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
3
20%
Ph phase_1
1
7%
Ph phase_2
9
60%
Ph phase_4
2
13%

Phase Distribution

1

Early Stage

9

Mid Stage

5

Late Stage

Phase Distribution15 total trials
Phase 1Safety & dosage
1(6.7%)
Phase 2Efficacy & side effects
9(60.0%)
Phase 3Large-scale testing
3(20.0%)
Phase 4Post-market surveillance
2(13.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

15

all time

Status Distribution
Active(5)
Completed(2)
Other(8)

Detailed Status

unknown8
Not yet recruiting3
Completed2
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
15
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (6.7%)
Phase 29 (60.0%)
Phase 33 (20.0%)
Phase 42 (13.3%)

Trials by Status

completed213%
not_yet_recruiting320%
recruiting213%
unknown853%

Recent Activity

Clinical Trials (15)

Showing 15 of 15 trials
NCT07093931Phase 4

Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer

Not Yet Recruiting
NCT06714383Phase 2

Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma

Recruiting
NCT06170697Phase 2

Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma

Unknown
NCT05780294Phase 3

A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC

Not Yet Recruiting
NCT05766605Phase 3

Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial

Unknown
NCT05701436Phase 3

Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial

Recruiting
NCT05546255Phase 2

Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer

Unknown
NCT04845490Phase 2

Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy

Not Yet Recruiting
NCT04808466Phase 2

Comparative Study of Lobaplatin and Paclitaxel in Advanced Gastric Cancer Patients With D2 Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy

Unknown
NCT03413436Phase 4

Lobaplation or Cisplatin in Adjuvant Chemotherapy for Esophageal Carcinoma

Completed
NCT03700359Phase 2

A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLC

Unknown
NCT03188497Phase 1

Dose Escalation of Lobaplatin Concurrent With IMRT for the Treatment of NPC: A Phase I Clinical Trial

Completed
NCT03210389Phase 2

A Clinical Trial of Chemotherapy With Lobaplatin and 5-FU in Recurrent Local or Distant Advanced NPC.

Unknown
NCT03117257Phase 2

Docetaxel and Loplatin Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced SCCHN

Unknown
NCT01483300Phase 2

Effectiveness and Toxicity of Gemcitabine/Lobaplatin Versus Gemcitabine/Cisplatin as Second-line Treatment in Metastatic Breast Cancer

Unknown

All 15 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
15